PMID- 14603790
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20191108
IS  - 0896-4327 (Print)
IS  - 0896-4327 (Linking)
VI  - 16
IP  - 5
DP  - 2003 Oct
TI  - The role of enoxaparin in interventional management of patients with acute 
      coronary syndromes.
PG  - 357-66
AB  - Interventional management strategies involving early angiography and percutaneous 
      coronary intervention (PCI) are increasingly widespread in the management of 
      patients with acute coronary syndromes (ACS). Notwithstanding the benefits of 
      early intervention, there is a significant risk of postprocedural thrombotic 
      complications and a need to optimize antithrombotic regimens for use before and 
      during PCI. It is clear that the current standard therapy with unfractionated 
      heparin (UFH) and aspirin can be improved upon, in terms of both efficacy and 
      safety. The low-molecular-weight heparin(s) (LMWHs) offer pharmacologic and 
      practical advantages over UFH. The LMWH enoxaparin has recently emerged as the 
      anticoagulant of choice for the acute management of ACS. Enoxaparin has also 
      demonstrated sustained benefits over UFH in patients proceeding to PCI, and as a 
      procedural anticoagulant. Combination therapy with enoxaparin and a glycoprotein 
      IIb/IIIa inhibitor may further improve the efficacy and safety of antithrombotic 
      treatment during coronary interventions, as a result of the drugs' complementary 
      mechanisms of action. Early clinical evidence supports the use of enoxaparin in 
      combination with glycoprotein IIb/IIIa inhibitors in high-risk patients with ACS. 
      Ongoing, large-scale, randomized controlled studies will help to clarify the role 
      of enoxaparin in interventional cardiology, either as the primary anticoagulant 
      or as part of a combination regimen, and to define optimal regimens for 
      treatment.
FAU - Grines, Cindy L
AU  - Grines CL
AD  - William Beaumont Hospital, Division of Cardiology, Cardiology Administration/3rd 
      Floor Heart Center, 3601 W. Thirteen Mile Road, Royal Oak, Michigan 48073-6769, 
      USA. Cgrines@smtpgw.beaumont.edu
FAU - O'Neill, William
AU  - O'Neill W
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
RN  - 0 (Anticoagulants)
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Enoxaparin)
SB  - IM
MH  - Acute Disease
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Blood Coagulation Factors/drug effects
MH  - Cardiac Catheterization/drug effects
MH  - Combined Modality Therapy
MH  - Coronary Disease/*drug therapy/pathology/surgery
MH  - Enoxaparin/pharmacology/*therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Syndrome
RF  - 53
EDAT- 2003/11/08 05:00
MHDA- 2003/12/20 05:00
CRDT- 2003/11/08 05:00
PHST- 2003/11/08 05:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/11/08 05:00 [entrez]
AID - 1000 [pii]
AID - 10.1046/j.1540-8183.2003.01000.x [doi]
PST - ppublish
SO  - J Interv Cardiol. 2003 Oct;16(5):357-66. doi: 10.1046/j.1540-8183.2003.01000.x.